Patient Transport News
-
How ReFlow Helped Get Zachary’s Hydrocephalus Under Control and Travel Across the Globe
Even before Zachary was born nearly 11 years ago, his parents Sherry and Jason knew that he was going to be a special boy – and a wonderful sibling to a twin sister! Zachary was born with spina bifida and hydrocephalus, both of which were diagnosed while in utero. As with many children in the hydrocephalus community, most parents have never heard of the condition, nor understand how it ...
-
FDA Establishes New Medical Device Category: FDA Authorization Now Required to Market UV Robots to Healthcare Facilities
The U.S. Food and Drug Administration (“FDA”) has announced a new medical device product classification “whole room microbial reduction device” which establishes FDA regulation of UV robots intended to reduce the number of pathogens in unoccupied patient rooms, operating rooms and other areas in healthcare facilities where non-critical medical devices are present. ...
-
Protea and Markonis celebrate the first 5 years of collaboration
This year Protea celebrates 5 years of collaboration with the Serbian company Markonis in the ambulance field for the Balkan area. Markonis is a renowned company based in Niš in Serbia specialized in the production and fitting of ambulances and special vehicles. With a long history of over 30 years, Markonis has established itself in the ambulance field as a reliable, experienced and ...
By ProTeA srl
-
Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics
Clinically validated lipid nanoparticle (LNP) delivery technology will further strengthen Bayer’s gene therapy portfolio High potency ionizable lipid technology and LNP carriers allow for efficient, targeted, and transient delivery of gene editing RNA components to the liver Bayer AG is joining forces with Acuitas Therapeutics, Inc., a biotechnology company specializing in the ...
By Bayer AG
-
enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical Operations
IRVINE, CA / August 16, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of venous disease, today announced the appointment of Kevin Belteau as Vice President of Clinical Operations. Mr. Belteau joins enVVeno Medical following a twenty-three-year career in clinical operations at ...
-
Gesynta Pharma completes patient enrollment in its Phase II study in systemic sclerosis
Gesynta Pharma AB today announces that all patients have been recruited for the company's clinical Phase II study with the drug candidate GS-248, which is being evaluated as a treatment for the rare disorder systemic sclerosis.The study is intended to demonstrate proof-of-concept and to evaluate the safety profile of GS-248. Top-line data is expected in the fall of 2022. Systemic ...
-
enVVeno Medical Announces the Issuance of a New Unique Category III CPT Code Covering the Insertion of a Bioprosthetic Valve into the Femoral Vein
New Current Procedural Terminology (CPT®) III code establishes a reimbursement pathway for the VenoValve The VenoValve is a potential first-in-class treatment for patients suffering from Chronic Venous Insufficiency (CVI) of the deep veins of the leg There are currently no effective treatments for patients with deep venous CVI The VenoValve is currently being evaluated in leading ...
-
Linear Health Sciences Announces Issuance of First US Patent
OKLAHOMA CITY – Linear Health Sciences today announced that the United States Patent and Trademark Office has issued the company’s first patent related to its flagship product, the Orchid Safety Release Valve™. US Patent No. 9,861,805 B2 covers wide-ranging claims behind the needless connector for use in medical access devices such as IV catheters. “The patent issuance ...
-
IV Dislodgement Is a Common Problem in Vascular Access, Clinicians Say
Portsmouth, N.H. – IV dislodgement is a near-daily problem for clinicians and their patients, according to a recent focus group of vascular access experts. The clinicians also reported there is a need for better technology to mitigate the potentially serious consequences of frequent IV dislodgements. “This research discussion addressed a frustrating problem that those of us in ...
-
NeuroOne Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the second quarter of fiscal year 2022 ended March 31, 2022. Second Quarter and Recent Business Updates Evo® sEEG electrode ...
-
The Neotec Program finances a new transport ventilator with ICU benefits
INBENTUS , with name Iconic Solutions by Murcia SL, is carrying out a project co-financed with European funds from the Recovery and Resilience Mechanism and "Subsidized by the CDTI" supported by the Ministry of Science and Innovation within the NEOTEC PROGRAM , called " TRANSPORT RESPIRATOR WITH ICU BENEFITS ” SNEO-20211086 The project runs from January 1, 2022 to December 31, ...
By Inbentus
-
Blogpost - Scientific proof of the effectiveness of the REAplan
Robot-assisted therapy (RAT) is of significant interest in early rehabilitation, when neuroplasticity is high but motor control is frequently insufficient for patients to independently practice functional movements. Many patients with stroke experience persistent upper limb (UL) impairments. This single-blind, randomized, controlled trial[i] explored the impact of partially substituting ...
By Axinesis
-
enVVeno Medical Announces New U.S. VenoValve Patent
Expanding patent portfolio bolsters protection of the Company’s lead product The VenoValve is a potential first-in-class treatment for patients suffering from Chronic Venous Insufficiency (CVI) of the deep veins of the leg There are currently no effective treatments for patients with deep venous CVI The VenoValve is currently being evaluated in leading hospitals throughout the U.S. in ...
-
Home Dialysis Patients Face Postcode Lottery of Care, New Report Finds
QUANTA Dialysis Technologies Ltd (“QUANTA” or the “Company”), a medical technology company committed to making kidney care more accessible with its SC+ haemodialysis system, has released a new report that suggests people with kidney failure who wish to do home dialysis face unequal access across the UK. The Bridging the Gap report finds that failure to offer such treatment ...
-
National Institute for Health and Care Excellence (NICE) Publishes Briefing on ReStore Soft Exo-Suit in the UK
ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company"), a manufacturer of robotic medical devices for individuals with lower limb disabilities, today announced its ReStore Soft Exo-Suit was the subject of a recent Medtech Innovation Briefing (MIB) by the UK's National Institute for Health and Care Excellence (NICE). These briefings are designed to support National Health Services (NHS) ...
-
Union Leader: Millyard lab will be used to manufacture human tissue for clinical trials
It’s been nearly five years since Dean Kamen announced the launch of BioFabUSA, a program of the Advanced Regenerative Manufacturing Institute to jump-start the large-scale production of synthetic human tissue. Under the direction of Chief Technology Officer Tom Bollenbach, BioFabUSA has created a “tissue foundry” as a working prototype to manufacture cells, which ...
-
Topline results from Phase 3 SPRINTER trial
Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces that the international Phase 3 SPRINTER trial of SNG001 in patients hospitalised with COVID-19 did not meet its primary or key secondary efficacy endpoints. SNG001 demonstrated a favourable safety profile and was well ...
-
Queen’s University Radiology Receives Hyperfine Portable MRI to Improve Access to Care for Canadian Patients in Remote Northern Communities
Hyperfine, Inc. (Nasdaq:HYPR), creator of Swoop®, the first FDA-cleared portable magnetic resonance imaging (MRI) system™, is proud to announce that Queen’s University and Kingston Health Sciences Centre are deploying a Swoop system as part of their health services benefitting six communities located in the James Bay and Hudson Bay Area. Until now, patients needing routine or ...
By Hyperfine
-
Improving the Patient Experience: Before, During, and After Office Procedures
Improving dermatology patients’ experience during dermatology procedures means more than simply providing top-notch aesthetic treatment. It requires thoughtful interactions that address every aspect of the patient's visit including their physical comfort, emotional state, and socioeconomic status. Patients increasingly choose healthcare providers who can respond to their specific needs. ...
-
Third Pole Therapeutics Closes $25M Financing - eNOfit Wearable Device Now Ready for Clinical Trials
eNOfit™, Third Pole’s novel nitric oxide mobile-wearable device designed to provide “on-the-go” treatment for patients suffering from severe COPD and ILD, to enter clinical trials in the second half of this year Funding will support device optimization and clinical trials; Pivotal trial data expected in the second half of 2023 Third Pole Therapeutics, a privately ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you